PRO96 RE-ASSESSEMENT OF ORPHAN DRUGS IN GERMAN BENEFIT...

PRO96 RE-ASSESSEMENT OF ORPHAN DRUGS IN GERMAN BENEFIT ASSESSMENT AFTER EXCEEDING 50-M-EURO SALES: EFFECTS ON ADDITIONAL BENEFIT AND REIMBURSEMENT PRICE

Ernst, N., Ecker, T.
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
22
Journal:
Value in Health
DOI:
10.1016/j.jval.2019.09.2426
Date:
November, 2019
File:
PDF, 320 KB
2019
Conversion to is in progress
Conversion to is failed